Pre-diyabette Beslenmenin Karaciğer Transkriptomiği ve Lipidomiği Üzerindeki Etkisi

Sade dilde özet

Bu çalışma, pre-diyabeti (prediabetes) olan kişilerde düşük yağlı ve yüksek yağlı beslenmenin karaciğerin gen ifadesi (transkriptomik) ve yağ profili (lipidomik) üzerindeki etkisini incelemektedir. Çalışmaya, 18-60 yaş arasında, sigara içmeyen ve belirli metabolik ölçütleri karşılayan kadın ve erkekler alınmaktadır. Çalışma faz uygulanmayan bir çalışma olup şu an katılımcı almamakta ancak devam etmektedir (active, not recruiting).

Yukarıdaki özet, resmî kaydın sade dile aktarılmış halidir. Orijinal İngilizce başlık referans için gösterilir.

Deney bilgileri

Faz

Faz dışı

Durum

Devam ediyor, katılım kapalı

Sponsor

Laval University

Müdahale

Low fat diet, High fat diet

Başlangıç

09.06.2023

Tahmini bitiş

31.12.2025

Ülkeler

Canada

İlgili genler

Merkezler

• Québec, Canada

Uygunluk kriterleri

Kriterler ClinicalTrials.gov kaydından orijinal İngilizce haliyle alınmıştır. Uygunluk kararını yalnızca deneyi yürüten ekip verebilir.

Inclusion Criteria:

* Males and females 18 to 60 years of age.
* Non-smoker
* Waist circumference \> 102 cm for men and \> 88 cm for women.
* Plasma triglyceride levels \> 1,7 mmol/L at the screening visit.
* Fasting plasma glucose levels \> 6,1 mmol/L at the screening visit.
* Fasting plasma insulin levels above the upper limit of normal at the screening visit.
* Subjects must be willing to give written informed consent and able to adhere to the diet schedule and visit schedule.
* Patients should be otherwise healthy, without abnormal renal function or coagulation.

Exclusion Criteria:

* Patients with extreme dyslipidemias, such as familial hypercholesterolemia will be excluded.
* Subjects will be excluded if they have cardiovascular disease (CHD, cerebrovascular disease or peripheral arterial disease) or if they are taking other medications known to affect lipoprotein metabolism (eg. steroids, beta blockers, thiazide diuretics, other lipid lowering agents, significant alcohol intake etc.).
* Subjects who are in a situation or have any condition that, in the opinion of the investigator, may interfere with optimal participation in the study.
* Individuals with a history of mental instability, drug or alcohol abuse within the past 2 years or individuals who have been treated or are being treated for severe psychiatric illness that, in the opinion of the investigator, may interfere with optimal participation in the study.
* Disorders of the hematologic, digestive, or central nervous systems, including cerebrovascular disease and degenerative disease, that would limit study evaluation or participation.
* Known impairment of renal function (creatinine \>2.0 mg/dL), dysproteinemia, nephrotic syndrome, or other renal disease.
* Subjects with coagulopathy (prothrombin time \[PT\] or partial thromboplastin time \[PTT\] at Visit 1 higher than 1.5 times control).
* Patients who are known to have tested positive for human immunodeficiency virus (HIV).
* Patients who have used any investigational drug within 30 days of the first clinic visit.
* Diabetic patients are excluded from the study. Uncontrolled endocrine or metabolic disease known to influence serum lipids or lipoproteins. Clinically euthyroid subjects on replacement doses of thyroid hormone are eligible for enrollment.